Brammer leans on Pall for $50m cell & gene therapy plant expansions

This year, Brammer Bio has invested in its biomanufacturing capabilities, with a $40m expansion at its late-stage and commercial-ready cell and gene therapy facility in Cambridge, Massachusetts​ and a $10m expansion at a Phase I/II plant in Alachua, Florida​.

And at Biotech Week Boston yesterday, Pall Life Science announced it had been chosen as a preferred technology partner “to deliver an end-to-end single-use platform solution from upstream to downstream,”​ according to Mario Philips, vice president and general manager of Pall Biotech.

The Alachua site will feature cell culture capabilities of up to 500L, while Cambridge will have a scale of up to 2,000L, both fully equipped by Pall. This includes Allegro STR single-use stirred-tank bioreactors range, fixed-bed bioreactors for the scale-up of adherent processes, and 25 bi-axial rocking bioreactors.

In the downstream, Pall will supply the sites single-use tangential flow filtration (TFF) systems, Allegro MVP systems for fluid automation, and Allegro single-use chromatography systems.

“With Pall’s critical process solutions and process support, we look forward to building on more than 100 executed projects and 150 clinical cell and gene therapy lots in Florida—including many first-in-human trials—and 600 plus commercial biologics batches produced in Massachusetts,”​ Brammer’s CSO Richard Snyder said in a statement.